trending Market Intelligence /marketintelligence/en/news-insights/trending/MXd31NClDPCxCo_d4dhhYA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Akari Therapeutics prices $17.4M offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Akari Therapeutics prices $17.4M offering

Akari Therapeutics PLC priced an underwritten public offering of 3,480,000 American depositary shares at $5 apiece to raise $17.4 million in gross proceeds.

The company also granted underwriters a 30-day option to buy up to an additional 522,000 of the ADSs offered.

Akari plans to use funds raised for general corporate purposes.

The offering is expected to close by Oct. 20 with Cantor Fitzgerald & Co., William Blair & Co. LLC and Canaccord Genuity Inc. acting as joint book-running managers.